Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
gH1-Qbeta
- Development stage
- Discontinued
- Lead developer
- Agency for Science, Technology and Research
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
gH1-Qbeta is a virus-like particle (VLP) vaccine candidate developed for the prevention of the 2009 H1N1 pandemic influenza. Developed through a collaboration between Singapore's Agency for Science, Technology and Research (A*STAR) and Cytos Biotechnology, the vaccine utilizes Cytos' proprietary bacteriophage Qbeta VLP technology as an immunological carrier. The vaccine consists of the globular head (gH) domain of the influenza hemagglutinin (HA) protein from the A/California/07/2009 (H1N1) strain chemically conjugated to the surface of the Qbeta VLP. This multivalent display of the antigen is designed to mimic the structure of a virus, thereby stimulating a robust B-cell response and the production of neutralizing antibodies without the use of live influenza virus. The vaccine was produced using a recombinant method in E. coli. Although it successfully completed a Phase I clinical trial in 2013 demonstrating safety and immunogenicity in healthy volunteers, further development was discontinued.
- Other names
- gH1-Qbeta vaccinegH-1-Qbeta vaccinegH 1-Qbeta vaccine
02
Targets
HA (Hemagglutinin)
Beyond the preview
Go deeper on gH1-Qbeta.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on gH1-Qbeta.